Candel Therapeutics (CADL) Free Cash Flow (2020 - 2025)
Candel Therapeutics (CADL) reported Free Cash Flow of -$10.5 million for Q4 2025, down 80.88% on a YoY basis from -$55.0 million in Q4 2024, and down 1.37% sequentially from -$10.4 million in Q3 2025.
Candel Therapeutics (CADL) Free Cash Flow (2020 - 2025) Analysis & Trends
Candel Therapeutics (CADL) has 6 years of Free Cash Flow data on file, last reported at -$10.5 million in Q4 2025.
- For the quarter ending Q4 2025, Free Cash Flow fell 80.88% year-over-year to -$10.5 million; the trailing twelve-month figure through Dec 2025 stood at -$38.4 million (down 42.18% YoY), and the FY2025 full-year result was -$38.4 million, down 42.18% from the prior year.
- Free Cash Flow fell to -$10.5 million in Q4 2025, from -$10.4 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$3.8 million in Q4 2021 to a low of -$11.0 million in Q1 2023.
- A 5-year average of -$7.7 million and a median of -$7.7 million in 2021 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow sank 417.85% in 2021 and gained 25.99% in 2024, its largest moves.
- Tracing CADL's Free Cash Flow over 5 years: stood at -$3.8 million in 2021, then slumped by 55.15% to -$5.9 million in 2022, then slumped by 32.48% to -$7.9 million in 2023, then grew by 25.99% to -$5.8 million in 2024, then plunged by 80.88% to -$10.5 million in 2025.
- Business Quant data shows CADL's Free Cash Flow at -$10.5 million in Q4 2025, -$10.4 million in Q3 2025, and -$8.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Candel Therapeutics | 542.51 Mn | 542.51 Mn | - | -10.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.52 Mn |
| Dec 31, 2025 | -10.52 Mn |
| Sep 30, 2025 | -10.38 Mn |
| Sep 30, 2025 | -10.38 Mn |
| Jun 30, 2025 | -8.91 Mn |
| Jun 30, 2025 | -8.91 Mn |
| Mar 31, 2025 | -8.63 Mn |
| Mar 31, 2025 | -8.63 Mn |
| Dec 31, 2024 | -5.82 Mn |
| Dec 31, 2024 | -5.82 Mn |
| Sep 30, 2024 | -6.57 Mn |
| Sep 30, 2024 | -6.57 Mn |
| Jun 30, 2024 | -6.20 Mn |
| Jun 30, 2024 | -6.20 Mn |
| Mar 31, 2024 | -8.45 Mn |
| Mar 31, 2024 | -8.45 Mn |
| Dec 31, 2023 | -7.86 Mn |
| Dec 31, 2023 | -7.86 Mn |
| Sep 30, 2023 | -8.81 Mn |
| Sep 30, 2023 | -8.81 Mn |